NF-κB in Hematological Malignancies
NF-κB (Nuclear Factor Κ-light-chain-enhancer of activated B cells) transcription factors are critical regulators of immunity, stress response, apoptosis, and differentiation. Molecular defects promoting the constitutive activation of canonical and non-canonical NF-κB signaling pathways contribute to...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2017-05-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2227-9059/5/2/27 |
| _version_ | 1811227243916034048 |
|---|---|
| author | Véronique Imbert Jean-François Peyron |
| author_facet | Véronique Imbert Jean-François Peyron |
| author_sort | Véronique Imbert |
| collection | DOAJ |
| description | NF-κB (Nuclear Factor Κ-light-chain-enhancer of activated B cells) transcription factors are critical regulators of immunity, stress response, apoptosis, and differentiation. Molecular defects promoting the constitutive activation of canonical and non-canonical NF-κB signaling pathways contribute to many diseases, including cancer, diabetes, chronic inflammation, and autoimmunity. In the present review, we focus our attention on the mechanisms of NF-κB deregulation in hematological malignancies. Key positive regulators of NF-κB signaling can act as oncogenes that are often prone to chromosomal translocation, amplifications, or activating mutations. Negative regulators of NF-κB have tumor suppressor functions, and are frequently inactivated either by genomic deletions or point mutations. NF-κB activation in tumoral cells is also driven by the microenvironment or chronic signaling that does not rely on genetic alterations. |
| first_indexed | 2024-04-12T09:39:20Z |
| format | Article |
| id | doaj.art-cc29d2b7aca74ff089cb028ba5d5ee7f |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-04-12T09:39:20Z |
| publishDate | 2017-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-cc29d2b7aca74ff089cb028ba5d5ee7f2022-12-22T03:38:08ZengMDPI AGBiomedicines2227-90592017-05-01522710.3390/biomedicines5020027biomedicines5020027NF-κB in Hematological MalignanciesVéronique Imbert0Jean-François Peyron1Centre Méditerranéen de Médecine Moléculaire, INSERM U1065, Université Côte d’Azur, 06204 Nice, FranceCentre Méditerranéen de Médecine Moléculaire, INSERM U1065, Université Côte d’Azur, 06204 Nice, FranceNF-κB (Nuclear Factor Κ-light-chain-enhancer of activated B cells) transcription factors are critical regulators of immunity, stress response, apoptosis, and differentiation. Molecular defects promoting the constitutive activation of canonical and non-canonical NF-κB signaling pathways contribute to many diseases, including cancer, diabetes, chronic inflammation, and autoimmunity. In the present review, we focus our attention on the mechanisms of NF-κB deregulation in hematological malignancies. Key positive regulators of NF-κB signaling can act as oncogenes that are often prone to chromosomal translocation, amplifications, or activating mutations. Negative regulators of NF-κB have tumor suppressor functions, and are frequently inactivated either by genomic deletions or point mutations. NF-κB activation in tumoral cells is also driven by the microenvironment or chronic signaling that does not rely on genetic alterations.http://www.mdpi.com/2227-9059/5/2/27NF-κBleukemialymphoma |
| spellingShingle | Véronique Imbert Jean-François Peyron NF-κB in Hematological Malignancies Biomedicines NF-κB leukemia lymphoma |
| title | NF-κB in Hematological Malignancies |
| title_full | NF-κB in Hematological Malignancies |
| title_fullStr | NF-κB in Hematological Malignancies |
| title_full_unstemmed | NF-κB in Hematological Malignancies |
| title_short | NF-κB in Hematological Malignancies |
| title_sort | nf κb in hematological malignancies |
| topic | NF-κB leukemia lymphoma |
| url | http://www.mdpi.com/2227-9059/5/2/27 |
| work_keys_str_mv | AT veroniqueimbert nfkbinhematologicalmalignancies AT jeanfrancoispeyron nfkbinhematologicalmalignancies |